January 18, 2016 News by BioNews Staff Bike With Multiple Sclerosis Symptoms Debuts for 2016 Australia Fundraising Race One of the teams participating in the 10th anniversary of the MS Melbourne Cycle,Ā an annual biking challenge to raise money for MS Australia,Ā has built a bicycle that as closely as possible replicatesĀ theĀ physical difficulties and discomforts that typify multiple sclerosis (MS). AĀ collaboration between the companyĀ Grey Australia, paralympic athlete Carol…
January 11, 2016 News by Charles Moore Can Cannabinoid Chewing Gum Treat Multiple Sclerosis Pain and Spasticity? MedChew Rx, by AXIM Biotechnology,Ā the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is movingĀ into clinical testing. If all goes well, the company plans for a global release date ofĀ 2017. Medical cannabis is believed to have considerable promise as a therapy for…
November 2, 2015 News by Patricia Silva, PhD New Muscle Spasticity Therapy Under Priority Review by FDA PathMaker Neurosystems Inc., a clinical-stage neuromodulation company focused on non-invasive therapies for neuromotor disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted the companyās MyoRegulatorā¢ PM-2200 systemĀ the Expedited Access Pathway (EAP) designation and priority processing status. The MyoRegulator is the first product of PathMaker…
October 23, 2015 News by Charles Moore Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) ā held in Barcelona October 7ā10, 2015 ā supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…
October 1, 2015 News by Patricia Silva, PhD FDA Accepts New Drug Application for Osmotica Pharmaceutical’s Ontinua ER for Spasticity in Multiple Sclerosis Osmotica Pharmaceutical Corp.Ā recently announced that the FDA accepted its New Drug Application (NDA) for OntinuaTMĀ ER.
August 24, 2015 News by Charles Moore Clinical Trials Study Cannabis Chewing Gum for MS-Associated Pain and Spasticity AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testingĀ a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…
October 15, 2014 News by BioNews Staff Spasticity Drug to be Tested on Multiple Sclerosis Patients in Early 2015 Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity ā a chronic condition associated with patients with brain disorders, including Multiple Sclerosis —Ā at the next American Neurological Associationās Annual Meeting in Baltimore, Maryland. The Phase 1 randomized,…
May 9, 2014 by Maureen Newman Sun Pharma-Sponsored Phase 3 Trial to Treat Spasticity Due to Multiple Sclerosis in Recruiting Patients One of the most common and troublesome symptoms of multiple sclerosis is spasticity. Patients with spasticity experience involuntary muscle spasms and muscle stiffness, which interfere with daily activities. An imbalance in the signals from the brain and spinal cord in the central nervous system increase the excitability of muscles,…